America’s COVID-19 death toll is expected to reach nearly 300,000 by December 1; however, consistent mask-wearing beginning today could save about 70,000 lives, according to new data from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington’s School of Medicine.
Al via una grande sperimentazione di fase 3 in Usa sugli anticorpi monoclonali contro Covid-19. I pazienti ricoverati con Covid-19 in alcuni ospedali selezionati in tutto il mondo potranno decidere di partecipare alla sperimentazione clinica avviata per testare la sicurezza e l'efficacia di questo potenziale nuovo trattamento per la malattia.
The Menarini Group and Radius Health, Inc. (Nasdaq: RDUS) announced today that the companies have entered into an exclusive global license agreement for development and commercialization of elacestrant.
The authors of the new research, from the University of Padova and at Imperial College London, published today in Nature, suggest asymptomatic or pre-symptomatic people are an important factor in the transmission of COVID-19. They also argue that widespread testing, isolating infected people, and a community lockdown effectively stopped the outbreak in its tracks. The town of Vò, with a population of nearly 3,200 people, experienced Italy’s first COVID-19 death on 21 February 2020.
A clinical trial to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with coronavirus disease 2019 (COVID-19) has been stopped by the National Institutes of Health.
Uno studio clinico per valutare la sicurezza e l'efficacia dell'idrossiclorochina, per il trattamento degli adulti ricoverati in ospedale con la malattia di coronavirus 2019 (COVID-19) è stato interrotto dal National Institutes of Health (NIH).
On June 16, 2020, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
On June 15, 2020, the Food and Drug Administration granted accelerated approval to lurbinectedin (ZEPZELCA, Pharma Mar S.A.) for adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.